Market closed
Relay Therapeutics/$RLAY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
$RLAY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
261
Website
RLAY Metrics
BasicAdvanced
$551M
-
-$2.36
1.61
-
Price and volume
Market cap
$551M
Beta
1.61
52-week high
$9.77
52-week low
$1.78
Average daily volume
2.7M
Financial strength
Current ratio
15.952
Quick ratio
15.402
Long term debt to equity
5.5
Total debt to equity
6.236
Management effectiveness
Return on assets (TTM)
-28.11%
Return on equity (TTM)
-44.15%
Valuation
Price to revenue (TTM)
46.4
Price to book
0.7
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-1.849
Growth
Revenue change (TTM)
-60.83%
Earnings per share change (TTM)
-15.27%
3-year revenue growth (CAGR)
48.94%
3-year earnings per share growth (CAGR)
-14.82%
What the Analysts think about RLAY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
RLAY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RLAY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RLAY News
AllArticlesVideos
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
GlobeNewsWire·6 days ago
Relay Therapeutics: Trying To Find That Right Price
Seeking Alpha·3 weeks ago
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $551M as of May 04, 2025.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of May 04, 2025.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of May 04, 2025.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.